Compare AGPU & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AGPU | BOLD |
|---|---|---|
| Founded | 2002 | 2018 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.8M | 36.5M |
| IPO Year | N/A | 2024 |
| Metric | AGPU | BOLD |
|---|---|---|
| Price | $5.59 | $1.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | ★ 3.8M | 402.4K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12,476.23 | N/A |
| Revenue Next Year | $55.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.96 |
| 52 Week High | $10.86 | $1.72 |
| Indicator | AGPU | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 56.63 | 65.14 |
| Support Level | $1.46 | $1.08 |
| Resistance Level | $6.46 | N/A |
| Average True Range (ATR) | 0.89 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 32.21 | 57.14 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.